Disorder of glycosylation
MONDO:0024322A disease that has its basis in the disruption of glycosylation.
Also known as: disorder of glycosylation, glycosylation disease
74 clinical trials for this condition and its sub-types, 0 tagged with Disorder of glycosylation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disorder of glycosylation
-
Disorder of GPI anchor biosynthesis 0 trials · 73 incl. sub-types
11 sub-types
- Paroxysmal nocturnal hemoglobinuria 73 trials Sub-types →
- Developmental and epileptic encephalopathy, 55 0 trials
- Developmental and epileptic encephalopathy, 77 0 trials
- Developmental and epileptic encephalopathy, 80 0 trials
- Glycosylphosphatidylinositol biosynthesis defect 15 0 trials
- Glycosylphosphatidylinositol biosynthesis defect 16 0 trials
- Glycosylphosphatidylinositol biosynthesis defect 17 0 trials
- Glycosylphosphatidylinositol biosynthesis defect 18 0 trials
- Glycosylphosphatidylinositol biosynthesis defect 25 0 trials
- Inborn disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation 0 trials Sub-types →
- Neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures 0 trials
-
DHDDS-CDG 1 trial
1 sub-type
- Retinitis pigmentosa 59 0 trials
-
Congenital myasthenic syndrome 12 0 trials
-
Schneckenbecken dysplasia 0 trials
Most studied deeper sub-types
-
PNH drug iptacopan tested in Real-World setting – but study cut short
Disease control Stopped earlyThis study looked at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) when used in everyday medical practice in Russia. Only 6 adults took part, and the study was terminated early. Researchers measured whether patients' hemoglobin levels…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
BCX9930 safety checked in PNH patients who benefited from treatment
Disease control Stopped earlyThis study looked at the long-term safety of BCX9930, an oral medication, for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants and aimed to monitor side effects. The study was terminated…
Phase 2 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC